Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Megan-Der-Yu Wang et al.|New England Journal of Medicine|2022Cited by 453
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopeniaTadeusz Robak, Stephen Jolles, Maciej Kaźmierczak et al.|Blood Advances|2020Cited by 109
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak et al.|Journal of Clinical Oncology|2022Cited by 93
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCRLuiza Handschuh, Marek Figlerowicz, Maciej Kaźmierczak et al.|International Journal of Oncology|2017Cited by 80
Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk ScoreJoanna Rupa‐Matysek, Mieczysław Komarnicki, Lidia Gil et al.|Medical Oncology|2017Cited by 49